HC Wainwright Issues Positive Estimate for SANA Earnings

Sana Biotechnology, Inc. (NASDAQ:SANA) – Research analysts at HC Wainwright increased their Q3 2024 earnings estimates for Sana Biotechnology in a research note issued on Tuesday, November 5th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.25) per share for the quarter, up from their previous forecast of ($0.30). HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Sana Biotechnology’s current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for Sana Biotechnology’s Q4 2024 earnings at ($0.19) EPS, FY2024 earnings at ($1.09) EPS, FY2025 earnings at ($0.77) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.72) EPS and FY2028 earnings at ($0.61) EPS.

A number of other equities analysts also recently commented on SANA. JMP Securities downgraded shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Citigroup raised their target price on shares of Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Friday, August 9th.

Sana Biotechnology Stock Down 9.1 %

NASDAQ:SANA opened at $3.10 on Thursday. The company has a market cap of $689.64 million, a P/E ratio of -2.72 and a beta of 1.44. Sana Biotechnology has a fifty-two week low of $2.85 and a fifty-two week high of $12.00. The firm’s 50 day moving average is $4.33 and its two-hundred day moving average is $5.86.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04).

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Blue Trust Inc. grew its position in Sana Biotechnology by 1,246.6% in the third quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock worth $55,000 after acquiring an additional 12,154 shares in the last quarter. Cornercap Investment Counsel Inc. bought a new stake in Sana Biotechnology in the third quarter worth approximately $67,000. Algert Global LLC bought a new stake in Sana Biotechnology in the second quarter worth approximately $73,000. XTX Topco Ltd bought a new stake in Sana Biotechnology in the second quarter worth approximately $100,000. Finally, Dark Forest Capital Management LP grew its position in Sana Biotechnology by 112.0% in the second quarter. Dark Forest Capital Management LP now owns 27,314 shares of the company’s stock worth $149,000 after acquiring an additional 14,430 shares in the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

Insider Activity at Sana Biotechnology

In other Sana Biotechnology news, Director Richard Mulligan sold 150,000 shares of the business’s stock in a transaction dated Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total transaction of $612,000.00. Following the sale, the director now directly owns 2,848,121 shares in the company, valued at approximately $11,620,333.68. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 31.10% of the stock is currently owned by insiders.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.